Real-life data of major and minor bleeding events with direct oral anticoagulants in the one-year follow-up period: The NOAC-TURK study
| Autor: | Lütfü Aşkın, Mahmut Şahin, Ahmet Yanık, Serkan Ünlü, Uğur Canpolat, Ümit Yaşar Sinan, Feyzullah Besli, Seçkin Pehlivanoğlu, Ömer Gedikli, Huseyin Altug Cakmak, Servet Altay |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Adult
medicine.medical_specialty One year follow up Adolescent Pyridones Administration Oral Hemorrhage Dabigatran Rivaroxaban Internal medicine Atrial Fibrillation medicine Diseases of the circulatory (Cardiovascular) system Humans In patient cardiovascular diseases Prospective Studies Prospective cohort study Original Investigation Aged Aged 80 and over business.industry Anticoagulants Atrial fibrillation Middle Aged medicine.disease Real life data Stroke RC666-701 cardiovascular system Apixaban Cardiology and Cardiovascular Medicine business medicine.drug Follow-Up Studies |
| Zdroj: | Anatol J Cardiol Anatolian Journal of Cardiology, Vol 25, Iss 3, Pp 196-204 (2021) |
| Popis: | OBJECTIVE: This study aimed to evaluate the safety of direct oral anticoagulants (DOACs) in patients with non-valvular atrial fibrillation (NVAF) during daily clinical practice. METHODS: This was a prospective study conducted between January 01, 2016, and April 01, 2017, in patients aged ≥18 years with a diagnosis of NVAF. We performed the study in 9 clinical centers from different regions of Turkey, and the mean follow-up period was 12+2 months. We investigated major and minor bleeding events of DOAC. RESULTS: A total of 1807 patients with NVAF were enrolled. The mean age of the patients was 73.6±10.2 years, CHA2DS2-VASc score was 3.6±1.4, and HAS-BLED score was 2±1.2. The most frequently prescribed DOAC was dabigatran 110 mg bid in 409 (22.6%) patients. The patients on apixaban 2.5 mg bid were older (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|